Publications by authors named "Patricia LoRusso"

100Publications

One Step at a Time - Clinical Evidence That KRAS Is Indeed Druggable.

N Engl J Med 2020 09 20;383(13):1277-1278. Epub 2020 Sep 20.

From Yale Cancer Center, New Haven, CT (P.M.L.); and the University of Michigan Rogel Cancer Center, Ann Arbor (J.S.S.-L.).

View Article and Find Full Text PDF
September 2020

Pre-clinical animal models are poor predictors of human toxicities in phase 1 oncology clinical trials.

Br J Cancer 2020 Nov 1;123(10):1496-1501. Epub 2020 Sep 1.

Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article and Find Full Text PDF
November 2020

Targeted therapy and immunotherapy: Emerging biomarkers in metastatic melanoma.

Pigment Cell Melanoma Res 2020 05 15;33(3):390-402. Epub 2020 Mar 15.

Robert H. Lurie Comprehensive Cancer Center, Northwestern University Medical Center, Chicago, IL, USA.

View Article and Find Full Text PDF
May 2020

Phase I trials as valid therapeutic options for patients with cancer.

Nat Rev Clin Oncol 2019 12 2;16(12):773-778. Epub 2019 Sep 2.

Center for Personalized Cancer Therapy, Department of Medicine, University of California San Diego Moores Cancer Center, La Jolla, CA, USA.

View Article and Find Full Text PDF
December 2019

Combination of triapine, olaparib, and cediranib suppresses progression of BRCA-wild type and PARP inhibitor-resistant epithelial ovarian cancer.

PLoS One 2018 16;13(11):e0207399. Epub 2018 Nov 16.

Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale University School of Medicine, New Haven, Connecticut, United States of America.

View Article and Find Full Text PDF
April 2019

Phase I study combining the aurora kinase a inhibitor alisertib with mFOLFOX in gastrointestinal cancer.

Invest New Drugs 2019 04 6;37(2):315-322. Epub 2018 Sep 6.

Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Vanderbilt University, 2220 Pierce Avenue, PRB 777, Nashville, TN, 37232, USA.

View Article and Find Full Text PDF
April 2019

Pharmacometabolomics Reveals Irinotecan Mechanism of Action in Cancer Patients.

J Clin Pharmacol 2019 01 27;59(1):20-34. Epub 2018 Jul 27.

Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, USA.

View Article and Find Full Text PDF
January 2019

Trastuzumab emtansine: determining its role in management of HER2+ breast cancer.

Future Oncol 2018 Mar 7;14(7):589-602. Epub 2017 Dec 7.

Yale Cancer Center, PO Box 208028, New Haven, CT 06510, USA.

View Article and Find Full Text PDF
March 2018

Precision Medicine: Progress, Pitfalls, and Promises.

Mol Cancer Ther 2017 12;16(12):2641-2644

The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article and Find Full Text PDF
December 2017

Twenty-First Century Precision Medicine in Oncology: Genomic Profiling in Patients With Cancer.

Mayo Clin Proc 2017 10;92(10):1583-1591

Yale Cancer Center, Yale School of Medicine, New Haven, CT.

View Article and Find Full Text PDF
October 2017

Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study.

J Clin Oncol 2017 Jan 21;35(2):157-165. Epub 2016 Nov 21.

Lucia Nogova, Reinhard Buettner, and Jürgen Wolf, University Hospital Cologne, Cologne; Martin Schuler, University Hospital Essen, and German Cancer Consortium (DKTK), Essen, Germany; Lecia V. Sequist, Massachusetts General Hospital; Geoffrey I. Shapiro, Dana-Farber Cancer Institute, Boston, MA; Jose Manuel Perez Garcia, Vall d'Hebron Institut d'Oncologia, Barcelona; Manuel Hidalgo, Spanish National Cancer Research Centre, Madrid, Spain; Fabrice Andre, Gustave Roussy, Villejuif; Jean-Pierre Delord, Institute Universitaire du Cancer de Toulouse, Toulouse; Philippe A. Cassier, Centre Regional Leon-Berard, Lyon; Mario Campone, Institute de Cancerologie de l'Ouest-René Gauducheau, Nantes, France; Jan H.M. Schellens, Netherlands Cancer Institute, Amsterdam, and Utrecht University, Utrecht, the Netherlands; D. Ross Camidge, University of Colorado, Aurora, CO; Ulka Vaishampayan, Barbara Ann Karmanos Cancer Institute, Detroit, MI; Howard Burris, Sarah Cannon Research Institute, Nashville; G. Gary Tian, The West Clinic, Memphis, TN; Zev A. Wainberg, UCLA School of Medicine, Los Angeles, CA; Wan-Teck Lim, National Cancer Centre, Singapore; Patricia LoRusso, Yale Cancer Center, New Haven, CT; Katie Parker, Xueying Chen, Somesh Choudhury, and Randi Isaacs, Novartis Pharmaceuticals Corporation, East Hanover, NJ; Dale Porter, Novartis Institutes for Biomedical Research, Cambridge, MA; Francois Ringeisen, Novartis Pharma AG; and Diana Graus-Porta, Novartis Institutes for Biomedical Research, Basel, Switzerland.

View Article and Find Full Text PDF
January 2017

A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumors.

Invest New Drugs 2017 02 21;35(1):47-58. Epub 2016 Sep 21.

Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA.

View Article and Find Full Text PDF
February 2017

Inhibition of the PI3K/AKT/mTOR Pathway in Solid Tumors.

J Clin Oncol 2016 11 30;34(31):3803-3815. Epub 2016 Sep 30.

Yale Cancer Center, New Haven, CT.

View Article and Find Full Text PDF
November 2016

An aqueous normal-phase chromatography coupled with tandem mass spectrometry method for determining unbound brain-to-plasma concentration ratio of AZD1775, a Wee1 kinase inhibitor, in patients with glioblastoma.

J Chromatogr B Analyt Technol Biomed Life Sci 2016 Aug 3;1028:25-32. Epub 2016 Jun 3.

Karmanos Cancer Institute, Wayne State University, Detroit, MI, 48201, USA. Electronic address:

View Article and Find Full Text PDF
August 2016

A pharmacodynamically guided dose selection of PF-00337210 in a phase I study in patients with advanced solid tumors.

Cancer Chemother Pharmacol 2016 Mar 20;77(3):527-38. Epub 2016 Jan 20.

Wisconsin Institute for Medical Research, University of Wisconsin Carbone Cancer Center, Room 7105, 1111 Highland Avenue, Madison, WI, 53705, USA.

View Article and Find Full Text PDF
March 2016

Next-Generation Sequencing to Guide Clinical Trials.

Clin Cancer Res 2015 Oct;21(20):4536-44

Yale Cancer Center, Yale School of Medicine, New Haven, Connecticut.

View Article and Find Full Text PDF
October 2015

Advancing Clinical Trials to Streamline Drug Development.

Clin Cancer Res 2015 Oct;21(20):4527-35

Merck Research Laboratories, North Wales, Pennsylvania.

View Article and Find Full Text PDF
October 2015

Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with erlotinib in patients with advanced solid tumors.

Cancer Chemother Pharmacol 2015 Nov 29;76(5):1025-32. Epub 2015 Sep 29.

Division of Hematology-Oncology, University of California Los Angeles, 2020 Santa Monica Blvd, Suite 600, Santa Monica, CA, 90404, USA.

View Article and Find Full Text PDF
November 2015

Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Metastatic Breast Cancer Previously Treated With Chemotherapy and 2 or More HER2-Targeted Agents: Results From the T-PAS Expanded Access Study.

Cancer J 2015 Sep-Oct;21(5):357-64

From the *Breast Cancer Research, Sarah Cannon Research Institute; and †Medical Oncology, Tennessee Oncology, PLLC, Nashville, TN; ‡Dana-Farber Cancer Institute, Boston, MA; §Smilow Cancer Center, Yale University, New Haven, CT; ∥AdvancedBC.org, New York, NY; ¶Genentech, Inc, South San Francisco, CA; and #Mayo Clinic, Jacksonville, FL.

View Article and Find Full Text PDF
June 2016

The Prevalence and Impact of Hyperglycemia and Hyperlipidemia in Patients With Advanced Cancer Receiving Combination Treatment With the Mammalian Target of Rapamycin Inhibitor Temsirolimus and Insulin Growth Factor-Receptor Antibody Cixutumumab.

Oncologist 2015 Jul 8;20(7):737-41. Epub 2015 Jun 8.

Departments of Endocrine Neoplasia and Hormonal Disorders, Head and Neck Surgery, Biostatistics, and Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, Michigan, USA; Cancer Therapy Evaluation Program, National Institutes of Health/National Cancer Institute, Rockville, Maryland, USA; Center for Personalized Cancer Therapy, University of California, San Diego, Moores Cancer Center, La Jolla, California, USA

View Article and Find Full Text PDF
July 2015

Phase I dose-escalation study of cabazitaxel administered in combination with gemcitabine in patients with metastatic or unresectable advanced solid malignancies.

Anticancer Drugs 2015 Aug;26(7):785-92

aDivision of Hematology/Oncology, University of New Mexico Cancer Center, Albuquerque, New Mexico bDivision of Hematology-Oncology, Henry-Joyce Cancer Clinic/The Vanderbilt Clinic, Nashville, Tennessee cYale Cancer Center, Yale University, New Haven, Connecticut dFox Chase Cancer Center, Philadelphia, Pennsylvania eDepartment of Medicine, Division of Hematology-Oncology, University of Cincinnati Cancer Institute, Cincinnati, Ohio fSanofi, Bridgewater, New Jersey, USA gSanofi, Montpellier, France.

View Article and Find Full Text PDF
August 2015

Achievements and challenges of molecular targeted therapy in melanoma.

Am Soc Clin Oncol Educ Book 2015 :177-86

From the Massachusetts General Hospital Cancer Center, Boston, MA; Yale Cancer Center, New Haven, CT; Yale University, New Haven, CT; University Hospital of Zurich, Zurich, Switzerland.

View Article and Find Full Text PDF
February 2016

Protein expression of DNA damage repair proteins dictates response to topoisomerase and PARP inhibitors in triple-negative breast cancer.

PLoS One 2015 16;10(3):e0119614. Epub 2015 Mar 16.

Department of Oncology, Wayne State University, Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States of America.

View Article and Find Full Text PDF
February 2016